APA引文

Okabe, S., Tauchi, T., Katagiri, S., Tanaka, Y., & Ohyashiki, K. (2014). Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells. BioMed Central.

Citação norma Chicago

Okabe, Seiichi, Tetsuzo Tauchi, Seiichiro Katagiri, Yuko Tanaka, and Kazuma Ohyashiki. Combination of the ABL Kinase Inhibitor Imatinib With the Janus Kinase 2 Inhibitor TG101348 for Targeting Residual BCR-ABL-positive Cells. BioMed Central, 2014.

MLA引文

Okabe, Seiichi, et al. Combination of the ABL Kinase Inhibitor Imatinib With the Janus Kinase 2 Inhibitor TG101348 for Targeting Residual BCR-ABL-positive Cells. BioMed Central, 2014.